A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE INVESTIGATIONAL DRUG PF-03446962 (A MONOCLONAL ANTIBODY WITH ANTIANGIOGENIC FEATURES) IN COMBINATION WITH BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS AFFECTED BY RECURRENT LIVER CANCER: